There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > REGULATORY
REGULATORY
- Two Healthcare Provider Reps at CSIMC Criticize Marketing of a Single Drug under Different Brand Names as “Undesirable”
August 24, 2012
- CSIMC Expert Subcommittee Favors Single Index for Efficacy Assessment of Medical Technology
August 24, 2012
- Drug Pricing Subcommittee Presents Negative Views on Reference Pricing System; “Concerns over Patient Copayment Increases”
August 24, 2012
- MHLW to Recommend Use of ReQuip CR Tablets
August 23, 2012
- CSIMC Approves Listing for 6 APIs/10 Products; Peak Sales Projected at 45.6 Billion Yen for Tenelia
August 23, 2012
- Nonpartisan League of Diet Members Aims to Submit Bill during Current Diet Session to Promote Measures against Strokes
August 23, 2012
- Introduction of RMPs Will Enable Clearer Strategies for Post-Marketing Safety: Ms Tawaragi of PFSB
August 23, 2012
- MHLW Budget Request to Focus on Life Innovation: Minister Komiyama
August 22, 2012
- PMDA’s Regulatory Consultation Service Off to Good Start, but More Effort Needed to Promote Face-to-Face Advisory Meetings: Dr Isobe
August 22, 2012
- Healthcare to Receive Priority in FY2013 Draft Budget Request Guidelines
August 21, 2012
- PAFSC’s 1st Committee to Review 7 Products Including Bayer Yakuhin’s AMD Drug on Aug. 31
August 20, 2012
- Subcommittee on Refractory Diseases Prepares to Improve Medical Expenditure Subsidies: Interim Report
August 20, 2012
- PMDA Meets Targets for FY2011, but Measures Needed to Reduce Applicants’ Processing Time: MHLW’s Evaluation Council
August 20, 2012
- MHLW Designates 4 Products Including Thyroid Cancer Agent as Orphan Drugs
August 20, 2012
- US Regulation Could Delay Introduction of PBRER as ICH Standard
August 17, 2012
- 215 Preliminary Interviews Given for Regulatory Strategy Consultation in 1st Year: PMDA
August 17, 2012
- MHLW Approves Allegra Generics of 3 Companies for Listing in December
August 16, 2012
- MHLW Announces that Manufacturer’s Suggested Retail Prices of DPT-IPV Start at 6,500 Yen
August 15, 2012
- MHLW Approves Additional Indications for 8 Products Including AZ’s Symbicort
August 15, 2012
- Neo-Morgan Laboratory Developing a Variety of Organisms Using “Disparity Mutagenesis Technology”
August 14, 2012
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…